Tris Pharma to Unveil Positive Phase 3 Results including a Strong Safety Profile Showcasing the Potential of Cebranopadol, an Investigational First-in-Class Dual-NMR Agonist for the Treatment of Pain, at the 2025 ASRA Annual Meeting (Businesswire) - Apr 30, 2025 - "Tris Pharma...announced data from cebranopadol, the company’s investigational dual-NMR agonist for the treatment of moderate-to-severe pain, featured in three poster presentations during the 50th Annual Regional Anesthesiology and Acute Pain Medicine Meeting (ASRA), taking place May 1-3, 2025, in Orlando, Florida...The poster presentations will highlight clinical trial results demonstrating the efficacy and safety of cebranopadol, reinforcing its potential as a much-needed novel treatment option for patients with moderate-to-severe acute pain. Tris Pharma will also host a symposium focused on dual-NMR agonism, a promising new mechanism of action in treating pain. Dual-NMR agonists have the potential to treat moderate-to-severe pain as effectively as opioids, and due to its novel mechanism, it can potentially do so with significantly lower risks of abuse, addiction and overdose."
Clinical data • Addiction (Opioid and Alcohol) • Pain
|